European Commission Expands PADCEV™ (enfortumab vedotin) Plus Keytruda® (pembrolizumab) Approval to Adults with Resectable Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Astellas Pharma (Press Release) 14h
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus Keytruda® (pembrolizumab) at Esmo 2026 Presidential Symposium Business Wire (Press Release) 19h
Gilead spends $1.28bn on PepStar’s potential Icotyde rival Pharmaceutical Technology 2h Gilead Sciences Biotech
Bottom of the Hill sold to biotech executive, will stay open as S.F. music venue San Francisco Chronicle 13h Biotech Biotechnology
Amgen vs. Eli Lilly: Does the GLP-1 mania make LLY stock a better buy in 2026? The Motley Fool 16h Eli Lilly Amgen Biotechnology
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall Hong Kong Standard 15h Moderna Pharma All sources
Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics Pharmaceutical Technology 3d Silence Therapeutics Pharma Biotechnology All sources
Merck opens new semiconductor materials facility in Korea The Korea Times 1d Merck Pharma IT All sources
Merck and Moderna Prepare FDA Filing for Personalized mRNA Melanoma Vaccine Paired with Keytruda After Phase 3 Results Medical Daily 3d KEYTRUDA Moderna Pharma
Gilead to pay $45 million to settle kickback charges filed by Texas attorney general STAT 6h Gilead Sciences Pharma
Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate NDA resubmission and PDUFA date of march 25, 2027 JCN Newswire 1d Biotechnology
